Introduction
============

Lung cancer is a leading cause of cancer mortality and accounted for 1.59 deaths worldwide in 2012.[@b1-lctt-6-013] Histopathologically, lung cancer is divided broadly into two groups, ie, non-small-cell lung cancer (NSCLC) and small cell lung cancer. The former accounts for 80%--85% of all lung cancer cases, and is further divided into several subgroups, ie, adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others. Most patients with NSCLC are diagnosed when their disease has already advanced locally or metastasized systemically. For inoperable patients with good performance status, chemotherapy is a standard treatment option.

Pemetrexed (Alimta^®^, Eli Lilly, Indianapolis, IN, USA) is a multitargeted antifolate drug that inhibits replication and survival of cancer cells by disrupting folate-dependent metabolic processes. During the past decade, this drug has come to have a leading role in front-line chemotherapy for patients with advanced non-squamous NSCLC, owing to its antitumor effects and mild toxicity.

When combined with platinum in a first-line regimen for non-squamous NSCLC, pemetrexed is superior or similar in efficacy and superior in toxicities to other third-generation antitumor drugs. There were three randomized Phase III studies that compared various endpoints between platinum plus pemetrexed and conventional platinum-based doublets in NSCLC ([Table 1](#t1-lctt-6-013){ref-type="table"}).[@b2-lctt-6-013]--[@b4-lctt-6-013] Among them, a milestone was the JMDB trial,[@b4-lctt-6-013] in which cisplatin plus pemetrexed showed non-inferiority in overall survival (OS) and better tolerability compared with cisplatin plus gemcitabine. In addition, this trial also indicated a histological difference in efficacy. Namely, pemetrexed improved OS for patients with non-squamous histology, but failed for patients with squamous histology. These results led to the approval of cisplatin plus pemetrexed for patients with advanced non-squamous NSCLC as a first-line regimen by the European Medicines Agency in April 2008 and by the US Food and Drug Administration in September 2008. Health-related quality of life and survival without grade 3 or 4 toxicity (SWT) was compared between carboplatin plus pemetrexed and carboplatin plus gemcitabine in a Norwegian study and between carboplatin plus pemetrexed and carboplatin plus docetaxel in a multinational study, respectively.[@b2-lctt-6-013],[@b3-lctt-6-013] Compared with control regimens, carboplatin plus pemetrexed provided similar health-related quality of life and OS in the Norwegian study,[@b2-lctt-6-013] and longer SWT but similar OS in the other study.[@b3-lctt-6-013] In addition, platinum plus pemetrexed was generally less toxic, except for severe nausea,[@b4-lctt-6-013] and generally caused less frequent severe leukopenia and neutropenia than control regimens in all studies ([Table 2](#t2-lctt-6-013){ref-type="table"}).[@b2-lctt-6-013]--[@b4-lctt-6-013]

Concerning cost-effectiveness, the platinum plus pemetrexed doublet is considered to be cost-effective, particularly in patients with non-squamous NSCLC histology ([Table 3](#t3-lctt-6-013){ref-type="table"}). There were two US studies with different approaches for first-line platinum plus pemetrexed.[@b5-lctt-6-013],[@b6-lctt-6-013] Based on a state transition model, Klein et al concluded that cisplatin plus pemetrexed was a cost-effective treatment for patients with non-squamous NSCLC when compared with cisplatin plus gemcitabine and a commonly mentioned but unwarranted threshold of US \$100,000 per life-year gained (LYG) in the USA.[@b5-lctt-6-013] Compared with a first-line combination of cisplatin plus gemcitabine, cisplatin plus pemetrexed led to an incremental cost per LYG of US \$104,577 for patients with NSCLC regardless of histological subtype, but a cost of US \$83,537 for patients with non-squamous NSCLC. Thus, considering the effect of prolongation of survival by the pemetrexed-containing regimen, pemetrexed was expensive but within the allowance. Based on indirect comparisons of the following three regimens in different studies because of no available head-to-head data, platinum plus pemetrexed was also considered more cost-effective than a triplet of bevacizumab combined with carboplatin plus paclitaxel, but controversial when compared with a doublet of carboplatin plus paclitaxel, as the pemetrexed-containing regimen was more costly but more effective than carboplatin plus paclitaxel.[@b5-lctt-6-013],[@b6-lctt-6-013] In September 2009, the National Institute for Health and Clinical Excellence (NICE) in the UK recommended pemetrexed in combination with cisplatin as an option for the first-line treatment of patients with non-squamous NSCLC, using the single technology appraisal process and based on the Evidence Review Group's exploratory analysis indicating that the incremental cost-effectiveness ratios (ICERs) for cisplatin plus pemetrexed compared with cisplatin plus gemcitabine were between £20,000 and £30,000 per quality-adjusted life-year (QALY) gained for non-squamous NSCLC and between £17,000 and £25,000 per QALY for adenocarcinoma or large-cell carcinoma, all under the willing-to-pay threshold of £30,000 per QALY gained.[@b7-lctt-6-013]

Options for maintenance therapy; continuation maintenance versus switch maintenance
===================================================================================

Maintenance therapy after 4--6 cycles of platinum-based induction chemotherapy is a standard first-line regimen for patients with advanced non-squamous NSCLC. Maintenance therapies are classified broadly into two types, ie, continuation maintenance and switch maintenance. The former is a continuation of one or two drugs used in the induction regimen and the latter involves introduction of an additional drug that was not used in the induction regimen. Switch maintenance can be understood as an early second-line therapy. Differences in efficacy between these two maintenance strategies remain unknown. A recent meta-analysis did not detect any significant differences in OS or progression-free survival (PFS) between these two maintenance strategies.[@b8-lctt-6-013] In contrast, another two meta-analyses showed favorable OS benefits for switch maintenance.[@b9-lctt-6-013],[@b10-lctt-6-013] In the study by Behera et al, switch maintenance provided significant benefit, both in PFS (hazard ratio \[HR\] 0.62, 95% confidence interval \[CI\] 0.57--0.67, *P*\<0.0001) and OS (HR 0.84, 95% CI 0.77--0.91, *P*=0.00026). In contrast, continuation maintenance modestly improved PFS (HR 0.90, 95% CI 0.85--0.95, *P*=0.007), but did not show an OS benefit (HR 0.927, 95% CI 0.78--1.09, *P*=0.33).[@b9-lctt-6-013] In the study by Cai et al, PFS was prolonged by both continuation (HR 0.54, 95% CI 0.46--0.63, *P*\<0.00001) and switch (HR 0.64, 95% CI 0.59--0.70, *P*\<0.00001) maintenance. Switch maintenance significantly improved OS (HR 0.80, 95% CI 0.72--0.90, *P*=0.0002), while continuation maintenance did not achieve a statistically significant improvement (HR 0.82, 95% CI 0.66--1.01, *P*=0.06).[@b10-lctt-6-013] From the viewpoint of clinical practice, these two maintenance strategies are very different, especially at the time of transition from the induction phase to the maintenance phase. Most oncologists would hesitate to discontinue an effective and tolerable induction regimen and then introduce a new drug with unknown efficacy and adverse effects. Thus, continuation maintenance is more acceptable than switch maintenance.

Currently, there are three drugs, comprising two molecular targeted drugs and one cytotoxic drug, approved as maintenance monotherapy after platinum-based induction chemotherapy: erlotinib (Tarceva^®^, Hoffmann-La Roche Ltd, Basel, Switzerland), a reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as switch maintenance for patients with any NSCLC histology; bevacizumab (Avastin^®^, Hoffmann-La Roche Ltd), a humanized monoclonal antibody that inhibits vascular endothelial growth factor and thereby angiogenesis, as continuation maintenance after platinum-based and bevacizumab-containing triplet induction for patients with non-squamous NSCLC; and pemetrexed as both types of maintenance for patients with non-squamous NSCLC.

Efficacy, safety, and tolerability of pemetrexed maintenance therapy
====================================================================

Pemetrexed is the only successful cytotoxic drug in maintenance therapy. There are three cytotoxic drugs that have been tested as candidates of continuation maintenance in phase III trials, but they showed different results ([Table 4](#t4-lctt-6-013){ref-type="table"}). Paclitaxel improved neither PFS nor OS,[@b11-lctt-6-013] gemcitabine prolonged only PFS but not OS,[@b12-lctt-6-013]--[@b14-lctt-6-013] and only pemetrexed successfully extended both PFS and OS.[@b15-lctt-6-013],[@b16-lctt-6-013] In addition, severe adverse effects were less frequent during the pemetrexed maintenance phase, compared indirectly with paclitaxel and gemcitabine maintenance ([Table 5](#t5-lctt-6-013){ref-type="table"}). Thus, pemetrexed had an advantage of less cumulative toxicity and better tolerability.

Erlotinib switch maintenance has never been compared with pemetrexed switch or continuation maintenance in a head-to-head Phase III trial. Bevacizumab combined with carboplatin plus paclitaxel has been directly compared with pemetrexed continuation maintenance in two Phase III studies ([Table 6](#t6-lctt-6-013){ref-type="table"}).[@b17-lctt-6-013],[@b18-lctt-6-013] These two studies, PRONOUNCE and ERACLE, defined unique primary endpoints of PFS without grade 4 adverse events[@b18-lctt-6-013] and difference in QoL,[@b17-lctt-6-013] respectively, instead of the usual efficacy parameters of PFS or OS. Thus, these studies provided little information with regard to deciding which regimen is superior as the first-line regimen for patients with non-squamous NSCLC.

Cost-effectiveness of pemetrexed maintenance therapy
====================================================

The cost-effectiveness of maintenance treatment with pemetrexed monotherapy is debatable ([Table 7](#t7-lctt-6-013){ref-type="table"}). There were five pharmacoeconomic analyses from various countries addressing this problem.[@b19-lctt-6-013]--[@b23-lctt-6-013] Four analyses were based on a switch maintenance trial (JMEN),[@b19-lctt-6-013]--[@b22-lctt-6-013] while the other was a continuation maintenance trial (PARAMOUNT).[@b23-lctt-6-013] Three of these analyses concluded that pemetrexed maintenance is not cost-effective, irrespective of switch and continuation.[@b21-lctt-6-013]--[@b23-lctt-6-013] In the pharmacoeconomic analyses from Japan, Switzerland, and the People's Republic of China, each willingness-to-pay threshold was assumed as ¥5--6 million per LYG (US \$43,478--52,174 per LYG),[@b22-lctt-6-013] €72,000 per QALY gained (Swiss federal court decision, November 23, 2010),[@b21-lctt-6-013] and US \$13,527 per QALY gained (3× the per capita gross domestic product),[@b23-lctt-6-013] respectively. All ICERs based on LYG or QALY were more than these thresholds.[@b21-lctt-6-013]--[@b23-lctt-6-013] The UK analysis also found that the most plausible ICER was £47,000 per QALY gained, which was above the standard NICE willingness-to-pay range (£20,000 to £30,000 per QALY).[@b19-lctt-6-013] Considering that maintenance treatment with pemetrexed fulfilled the end-of-life criteria, NICE in the UK optionally recommended switch maintenance by pemetrexed only for patients with non-squamous histology.[@b24-lctt-6-013] In contrast, NICE did not recommend continuation maintenance by pemetrexed because the most plausible ICER, approximately £74,500 per QALY gained, was higher than that normally considered to be cost-effective, even if the supplementary advice of NICE on end-of-life treatments was taken into consideration.[@b25-lctt-6-013] The US analysis indicated that pemetrexed may be considered cost-effective.[@b20-lctt-6-013] The ICER for pemetrexed to observation alone, ie, US \$122,371, may not be cost-effective when compared with a commonly mentioned threshold of US \$100,000 per LYG, but may be cost-effective when compared with a range of US \$95,000 to US \$264,000 per LYG, a recently revised plausible lower and upper bounds for cost-effectiveness decision rule in the USA.[@b26-lctt-6-013]

Comparison of cost-effectiveness between different types of maintenance is more difficult because of a lack of head-to-head clinical trials. Three studies have indirectly compared direct medical costs between maintenance with pemetrexed and maintenance with another drug ([Table 8](#t8-lctt-6-013){ref-type="table"}).[@b20-lctt-6-013],[@b27-lctt-6-013],[@b28-lctt-6-013] A US study showed that pemetrexed maintenance is more cost-effective for patients with non-squamous NSCLC than erlotinib, because the ICER for pemetrexed versus erlotinib (US \$150,260/LYG) is within the acceptable range of willingness to pay.[@b20-lctt-6-013] Another UK study also showed a clear advantage in favor of pemetrexed, ICER for erlotinib versus pemetrexed, £84,029/QALY gained.[@b27-lctt-6-013] In contrast, a European cross-market cost comparison showed that total monthly treatment costs per patient, including acquisition costs, administration costs, and costs of treating adverse events, were more reasonable for erlotinib than for pemetrexed, ie, €2,140 for erlotinib versus €3,453 for pemetrexed in France, €2,732 versus €5,534 in Germany, €1,518 versus €2,921 in Italy, and €2,048 versus €3,164 in Spain.[@b28-lctt-6-013] Thus, it remains unknown which maintenance strategy is the most cost-effective.

There were many study limitations in these pharmacoeconomic analyses; for example, a lack of clinical trials and detailed information about quality of life, imbalanced accrual in trials, and a variety of medical services among countries and territories. A Japanese study of direct medical cost by Tsuchiya et al[@b22-lctt-6-013] was based on clinical results of JMEN study[@b29-lctt-6-013] and Japanese health care system. Although the JMEN study included 32% of Asian population in pemetrexed switch maintenance group mainly from the People's Republic of China and Korea, no Japanese patient participated in this trial. The PARAMOUNT trial, undertaken in 93 center in 16 countries, included Asian population in only 4% of all cases.[@b30-lctt-6-013] Therefore, we Japanese and Asian can not refer to clinical results of this trial for a pharmacoeconomic study. There were three Japanese single-arm, Phase II studies evaluating a combination of carboplatin plus pemetrexed followed by pemetrexed maintenance for patients with non-squamous NSCLC. These trials provided an impressive median OS of more than 20 months not only from maintenance chemotherapy in patients who had received maintenance therapy[@b31-lctt-6-013],[@b32-lctt-6-013] but also from induction chemotherapy in all enrolled patients.[@b32-lctt-6-013],[@b33-lctt-6-013] In contrast, the JMEN and PARAMOUNT studies showed a median OS of 16.5 and 16.9 months, respectively, from induction chemotherapy for patients who had proceeded into the maintenance phase ([Table 9](#t9-lctt-6-013){ref-type="table"}).[@b15-lctt-6-013],[@b16-lctt-6-013],[@b29-lctt-6-013] OS in the Japanese single-arm, Phase II studies was much longer (by approximately 4 months) than in the multinational randomized placebo-controlled studies. Thus, the Japanese medical economic study possibly underestimated pemetrexed maintenance when based on clinical data from other ethnic groups and countries. Further studies and discussions are warranted with regard to pemetrexed maintenance.

Future directions
=================

A recent interesting challenge is doublet combination maintenance ([Table 6](#t6-lctt-6-013){ref-type="table"}).[@b34-lctt-6-013]--[@b36-lctt-6-013] We may have to consider EGFR mutation status for selection of a combination pattern. For patients with non-squamous NSCLC histology and positive EGFR mutation status, combination patterns of EGFR TKI with pemetrexed or bevacizumab are promising. A randomized Phase III trial is underway comparing gefitinib monotherapy with doublet continuation maintenance of pemetrexed plus gefitinib after triplet induction with carboplatin, pemetrexed, and gefitinib in patients with non-squamous NSCLC and positive EGFR mutations (NEJ009, trial number: UMIN000006340). This study potentially develops a first-line regimen for such patients. On the other hand, combination maintenance of bevacizumab plus an EGFR TKI is an alternative candidate treatment for these patients. Erlotinib provided an add-on effect with regard to PFS (bevacizumab plus placebo versus bevacizumab plus erlotinib; 3.7 versus 4.8 months from time of random assignment after induction chemotherapy, HR 0.71, 95% CI 0.58--0.86, *P*\<0.001), but failed in OS (13.3 versus 14.4 months, respectively, HR 0.92, 95% CI 0.70--1.21, *P*=0.5341), when a maintenance combination of erlotinib plus bevacizumab was introduced after four cycles of a bevacizumab-containing platinum-doublet chemotherapy for NSCLC patients who had not been selected by EGFR mutation status (ATLAS).[@b37-lctt-6-013] For a subgroup with active EGFR mutations, compared with the wild-type subgroup, this combination maintenance therapy also achieved greater improvement in PFS (HR 0.44, 95% CI 0.22--0.86 for the EGFR mutation-positive subgroup \[n=52\] versus HR 0.85, 95% CI 0.64--1.13 for the EGFR wild-type subgroup \[n=295\]), but there was no statistically significant difference in OS outcome (HR 0.46, 95% CI 0.21--1.02 versus HR 0.86, 95% CI 0.65--1.15, respectively). Thus, for patients with wild-type EGFR and unknown EGFR mutation status, maintenance therapy of bevacizumab plus erlotinib is not recommended, while subgroup analyses of this randomized Phase III study suggested a potential efficacy of this maintenance combination for patients with active EGFR mutations. A recent randomized Phase II study in Japan (JO25567) also demonstrated that first-line bevacizumab plus erlotinib markedly improved PFS compared with erlotinib alone (16.0 months for erlotinib plus bevacizumab \[n=77\] versus 9.7 months for erlotinib alone \[n=77\], HR 0.54, 95% CI 0.36--0.79, *P*=0.0015).[@b38-lctt-6-013] This study suggests that, for patients with active EGFR mutation status, combination of these two molecularly targeted drugs potentially yields a better survival benefit than erlotinib alone. We hope that this combination is beneficial in the maintenance setting, as well as in the first-line setting.

For patients with non-squamous NSCLC and wild-type or unknown EGFR mutation status, pemetrexed plus bevacizumab is possibly promising. Compared with bevacizumab alone, continuation maintenance of pemetrexed plus bevacizumab significantly prolonged PFS by a median of 3.7 months, but did not achieve a significant improvement in OS, despite a difference of 3.9 months in median OS after four cycles of bevacizumab combined with cisplatin plus pemetrexed (AVAPERL).[@b35-lctt-6-013] Another Phase III study (PointBreak) showed that continuation maintenance of pemetrexed plus bevacizumab after an induction triplet of bevacizumab combined with carboplatin plus pemetrexed was similar in OS but significantly superior in PFS when compared with continuation maintenance of bevacizumab alone after bevacizumab combined with carboplatin plus paclitaxel.[@b36-lctt-6-013] Thus, even the combination of pemetrexed plus bevacizumab remains unable to show an OS benefit when compared with bevacizumab alone. Adverse effects of anemia, thrombocytopenia, and fatigue were significantly more frequent on combination maintenance than on bevacizumab alone in the PointBreak trial ([Table 10](#t10-lctt-6-013){ref-type="table"}).[@b36-lctt-6-013] Benefit in terms of cost-effectiveness should be investigated for these combination maintenance therapies when their significant survival benefits are demonstrated, because these drugs are all very expensive.

For the future, we may need to narrow the core patients who are predicted to benefit from maintenance therapy with pemetrexed or other drugs. Hence, more clear-cut markers are required, such as EGFR mutation status for NSCLC. The most promising predictive biomarker of the efficacy of pemetrexed at this time is the thymidylate synthase expression level. Basic research is warranted to identify a reliable biomarker than can predict the clinical benefit of pemetrexed. These personalized therapies represent appropriate treatment options and result in cost savings when using expensive drugs. Investigation of selection or exclusion biomarkers is warranted.
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###### 

Phase III studies of combinations of pemetrexed plus platinum compared with standard platinum-based doublets

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                        Primary endpoint                                  n                              Regimens   RR (%)         PFS (M)   HR\
                                                                                                                                                                        *P*-value
  ------------------------------------------------ ------------------------------------------------- ------------------------------ ---------- -------------- --------- --------------
  Scagliottii et al[@b4-lctt-6-013] (JMDB trial)   OS[a](#tfn1-lctt-6-013){ref-type="table-fn"}      All NSCLC, entire population                                       

  862                                              CDDP + PEM                                        30.6                           4.8        HR 1.04        10.3      HR 0.94

  863                                              CDDP + GEM ×6 cycles                              28.2                           5.1        Non-inferior   10.3      Non-inferior

  Non-SQ NSCLC subgroup                                                                                                                                                 

  512                                              CDDP + PEM                                        ND                             5.3        HR 0.90        11.8      HR 0.81

  488                                              CDDP + GEM                                        ND                             4.7        ND             10.4      *P*=0.005

  Grønberg et al[@b2-lctt-6-013]                   HRQoL[b](#tfn2-lctt-6-013){ref-type="table-fn"}   All NSCLC, entire population                                       

  225                                              CBDCA + PEM                                       ND                             ND         ND             7.3       HR ND

  221                                              CBDCA + GEM ×4 cycles                             ND                             ND         ND             7.0       *P*=0.63

  Non-SQ NSCLC subgroup                                                                                                                                                 

  127                                              CBDCA + PEM                                       ND                             ND         ND             7.8       HR ND

  121                                              CBDCA + GEM                                       ND                             ND         ND             7.5       *P*=0.77

  Rodrigues-Pereira et al[@b3-lctt-6-013]          SWT                                               All non-SQ NSCLC                                                   

  128                                              CBDCA + PEM                                       34.0                           5.8        HR 0.91        14.9      HR 0.93

  132                                              CBDCA + DTX ×6 cycles                             22.9                           6.0        *P*=0.534      14.7      *P*=0.698

                                                                                                                                                              SWT       

  128                                              CBDCA + PEM                                                                                                3.2       HR 0.45

  132                                              CBDCA + DTX                                                                                                0.7       *P*\<0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Non-inferiority design;

defined as the four clinically relevant domains of global quality of life, nausea/vomiting, dyspnea and fatigue, and assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (QLQ-C30) and the lung cancer--specific module LC13 during the first 20 weeks.

**Abbreviations:** CBDCA, carboplatin; CDDP, cisplatin; DTX, docetaxel; GEM, gemcitabine; HR, hazard ratio; HRQoL, health-related quality of life; M, months; ND, not described; RR, response rate; OS, overall survival; PEM, pemetrexed; PFS, progression-free survival; SQ, squamous cell carcinoma; SWT, survival without treatment-emergent grade 3/4 toxicity.

###### 

Comparison of statistically significant adverse effects between pemetrexed-containing and control regimens

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                              Scagliotti et al[@b4-lctt-6-013]\                Grønberg et al[@b2-lctt-6-013]   Rodrigues-Pereira et al[@b3-lctt-6-013]                                                               
                                         (JMDB trial)                                                                                                                                                                            
  -------------------------------------- ------------------------------------------------ -------------------------------- ---------------------------------------------- ----- ------------------------------------------------ ------
  n                                      839                                              830                              219                                            217   106                                              105

  Hematologic                                                                                                                                                                                                                    

   Leukopenia, grade 3--4 (%)            4.8[a](#tfn4-lctt-6-013){ref-type="table-fn"}    7.6                              23[a](#tfn4-lctt-6-013){ref-type="table-fn"}   46    16.0[a](#tfn4-lctt-6-013){ref-type="table-fn"}   40.0

   Neutropenia, grade 3--4 (%)           15.1[a](#tfn4-lctt-6-013){ref-type="table-fn"}   26.7                             40[a](#tfn4-lctt-6-013){ref-type="table-fn"}   51    33.0[a](#tfn4-lctt-6-013){ref-type="table-fn"}   64.8

   Anemia, grade 3--4 (%)                5.6[a](#tfn4-lctt-6-013){ref-type="table-fn"}    9.9                              13                                             13    12.3[a](#tfn4-lctt-6-013){ref-type="table-fn"}   1.9

   Thrombocytopenia, grade 3--4 (%)      4.1[a](#tfn4-lctt-6-013){ref-type="table-fn"}    12.7                             24[a](#tfn4-lctt-6-013){ref-type="table-fn"}   56    9.4                                              2.9

  Non-hematologic                                                                                                                                                                                                                

   Febrile neutropenia, grade 3--4 (%)   1.3[a](#tfn4-lctt-6-013){ref-type="table-fn"}    3.7                              ND                                             ND    0[a](#tfn4-lctt-6-013){ref-type="table-fn"}      8.9

   Alopecia, any grade (%)               11.9[a](#tfn4-lctt-6-013){ref-type="table-fn"}   21.4                             ND                                             ND    8.5[a](#tfn4-lctt-6-013){ref-type="table-fn"}    42.9

   Nausea, grade 3--4 (%)                7.2[a](#tfn4-lctt-6-013){ref-type="table-fn"}    3.9                              3                                              4     0.9                                              1.0

   Diarrhea, any grade (%)               ND                                               ND                               ND                                             ND    6.6[a](#tfn4-lctt-6-013){ref-type="table-fn"}    20.0

   Abdominal pain, any grade (%)         ND                                               ND                               ND                                             ND    1.9[a](#tfn4-lctt-6-013){ref-type="table-fn"}    9.5
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Statistically significant (*P*\<0.05).

**Abbreviations:** CBDCA, carboplatin; CDDP, cisplatin; DTX, docetaxel; GEM, gemcitabine; ND, not described; PEM, pemetrexed.

###### 

Comparison in cost-effectiveness of direct medical costs between first-line pemetrexed-containing regimen with another platinum-doublet regimen: study deigns and results (monetary unit, US \$)

  Reference                                            Methods, cost and outcome discount, study perspective, time frame                         Data sources                                                                                                       Study population                                                                 Regimen                              Histology    Cost           LYG or OS[a](#tfn6-lctt-6-013){ref-type="table-fn"}   QALY     ICER[a](#tfn6-lctt-6-013){ref-type="table-fn"} / LYG   ICER / QALY
  ---------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------- ------------------------------------ ------------ -------------- ----------------------------------------------------- -------- ------------------------------------------------------ -------------
  Klein et al[@b5-lctt-6-013] (US)                     Semi-Markov model No discount U.S. payer's perspective Time frame; 2 year                 Clinical parameters; RCT (JMDB) Cost; Medicare reimbursement rates and average doses, PharMetrics claim database   Chemotherapy-naïve, stage IIIB/IV, non-SQ or all histology NSCLC, BSA 1.8 m^2^   CDDP + PEM                           Non-SQ       \$ 65,517      0.9652 Y                                              0.5016                                                          
                                                       All NSCLC                                                                                 \$ 66,606                                                                                                          0.9587 Y                                                                         0.4943                                                                                                                                                                                 
  CDDP + GEM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                     Incremental CDDP +PEM to CDDP+GEM                                                                                                                                                      
                                                       Non-SQ                                                                                    \$ 61,008                                                                                                          0.9112 Y                                                                         0.4676                               \$ 83,537    \$ 132,829                                                                                                                           
                                                       All NSCLC                                                                                 \$ 61,535                                                                                                          0.9102 Y                                                                         0.4661                               \$ 104,577   \$ 179,597                                                                                                                           
  CBDCA + PTX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                     Incremental CDDP +PEM to CBDCA+PTX                                                                                                                                                     
                                                       Non-SQ                                                                                    \$ 52,885                                                                                                          0.8945 Y                                                                         0.4513                               \$ 178,613   \$ 250,992                                                                                                                           
                                                       All NSCLC                                                                                 \$ 50,283                                                                                                          0.8882 Y                                                                         0.4469                               \$ 231,291   \$ 343,870                                                                                                                           
  CBDCA + PTX + Bev → Bev maintenance (Bev 15 mg/kg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                    Incremental CBDCA +PTX +Bev→Bev to CDDP+PEM                                                                                                                                                                                                                             
                                                       Non-SQ                                                                                    \$ 90,044                                                                                                          1.0379 Y                                                                         0.5260                               \$ 337,179   \$ 1,006,065                                                                                                                         
  Shah et al[@b6-lctt-6-013] (US)                      Retrospective cohort study of real world data documented in PMS data Time frame; 1 year   ION clinical oncology database, PMS data, SSA's Death Index Master file                                            First-line treatment between 2006 and 2009, advanced non-SQ NSCLC                Platinum + PEM                       Non-SQ       \$ 33,969      190 days                                              ND                                                              
  CBDCA + PTX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                    Incremental CBDCA+PTX to Platinum+PEM for OS                                                                                                                                                                                                                            
                                                                                                                                                 \$14,832                                                                                                           132 days                                                                         ND                                   \$ 330       ND                                                                                                                                   
  CBDCA + PTX + Bev → Bev maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                 Incremental CBDCA +PTX+Bev→Bev to Platinum +PE M for OS                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                 \$ 53,915                                                                                                          163 days                                                                         ND                                   -\$ 739      ND                                                                                                                                   

**Notes:**

Studies by Klein et al and by Shah et al presented LYG (years) and OS (days), ICER (cost / LYG, US \$) and mean incremental cost/day (US \$), respectively.

**Abbreviations:** BSA, body surface area; Bev, bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; ICER, incremental cost-effectiveness ratio; ION, International Oncology Network; LYG, life-year gained; ND, not described; NSCLC, non-small cell lung cancer; OS, overall survival; PEM, pemetrexed; PTX, paclitaxel; QALY, quality-adjusted life-year; SQ, squamous cell carcinoma; RCT, randomized controlled trial; PMS, practice management system; SSA, Social Security Administration; Y, years.

###### 

Phase III studies comparing a maintenance cytotoxic monotherapy with observation alone after induction chemotherapy

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                             PEP                                                        n                                                           Induction                                                                        Maintenance                                                 PFS or TTP (M)   HR\         OS (M)   HR\
                                                                                                                                                                                                                                                                                                                                                             *P*-value            *P*-value
  --------------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------- ---------------- ----------- -------- -----------
  **Continuation maintenance**                                                                                                                                                                                                                                                                                                                                                    

  Belani et al[@b11-lctt-6-013]                                         RR                                                         401 enrolled                                                3 regimens of CBDCA + PTX (arm 1--3)[a](#tfn8-lctt-6-013){ref-type="table-fn"}                                                                                                     

  TTP                                                                   130 randomized                                             Survival from randomization before induction chemotherapy                                                                                                                                                                                      

  65                                                                    w PTX                                                      8.9                                                         *P*=0.124                                                                        17.5                                                        *P*=0.243                             

  65                                                                    Obs                                                        6.8                                                                                                                                          14.0                                                                                              

  Brodowicz et al[@b13-lctt-6-013] (CECOG trial)                        TTP                                                        352 induction                                               CDDP + GEM ×4 cycles                                                                                                                                                               

  257 non-PD                                                                                                                                                                                                                                                                                                                                                                      

  215 randomized                                                        Survival from first treatment administration                                                                                                                                                                                                                                                              

  138                                                                   GEM                                                        6.6                                                         HR ND                                                                            13.0                                                        HR ND                                 

  68                                                                    Obs                                                        5.0                                                         *P*\<0.001                                                                       11.0                                                        *P*=0.195                             

                                                                        Survival from randomization after induction chemotherapy                                                                                                                                                                                                                                                  

  138                                                                   GEM                                                        3.6                                                         HR ND                                                                            10.2                                                        HR ND                                 

  68                                                                    Obs                                                        2.0                                                         *P*\<0.001                                                                       8.1                                                         *P*=0.172                             

  Belani et al[@b12-lctt-6-013]                                         OS                                                         519 enrolled                                                CBDCA + GEM ×4 cycles                                                                                                                                                              

  255 randomized                                                        Probably from randomization after induction chemotherapy                                                                                                                                                                                                                                                  

  128                                                                   GEM                                                        3.9                                                         HR ND                                                                            8.0                                                         HR 0.97                               

  127                                                                   Obs                                                        3.8                                                         *P*-value ND                                                                     9.3                                                         *P*=0.84                              

  Perol et al[@b14-lctt-6-013] (IFCT-GFPC0502 trial)                    PFS                                                        834 enrolled                                                CDDP + GEM ×4 cycles                                                                                                                                                               

  464 randomized                                                        Survival from randomization after induction chemotherapy                                                                                                                                                                                                                                                  

  154                                                                   GEM                                                        3.8                                                         HR 0.56                                                                          12.1                                                        HR 0.89                               

  155                                                                   Obs                                                        1.9                                                         *P*\<0.001                                                                       10.8                                                        *P*=0.3867                            

  Paz-Ares et al[@b15-lctt-6-013],[@b16-lctt-6-013] (PARAMOUNT trial)   PFS                                                        939 induction                                               CDDP + PEM ×4 cycles                                                             OS of randomly assigned patients, from start of induction                                         

  539 non-PD                                                            chemotherapy                                                                                                                                                                                                                                                                                              

  359                                                                   PEM                                                                                                                                                                                                     16.9                                                        HR 0.79                               

  180                                                                   Obs                                                                                                                                                                                                     14.0                                                        *P*=0.0191                            

                                                                        Survival from randomization after induction chemotherapy                                                                                                                                                                                                                                                  

  359                                                                   PEM                                                        4.4                                                         HR 0.60                                                                          13.9                                                        HR 0.78                               

  180                                                                   Obs                                                        2.8                                                         *P*\<0.001                                                                       11.0                                                        *P*=0.0198                            

  **Switch maintenance**                                                                                                                                                                                                                                                                                                                                                          

  Ciuleanu et al[@b29-lctt-6-013] (JMEN trial)                          PFS                                                                                                                    Plt-based regimens ×4 cycles                                                     Survival from randomization after induction chemotherapy                                          

  441                                                                   PEM                                                        4.3                                                         HR 0.50                                                                          13.4                                                        HR 0.79                               

  222                                                                   Placebo                                                    2.6                                                         *P*\<0.0001                                                                      10.6                                                        *P*=0.012                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Arm 1, CBDCA (AUC 6 mg/mL ⋅ min, day 1) plus PTX (100 mg/m^2^, days 1, 8, and 15) every 4 weeks; arm 2, CBDCA (AUC 2 mg/mL min, days 1, 8, and 15) plus PTX (100 mg/m^2^, days 1, 8, and 15) every 4 weeks; arm 3, CBDCA (AUC 2 mg/mL ⋅ min) plus PTX (150 mg/m^2^ in cycle 1 and 100 mg/m^2^ in cycle 2) weekly for 6 of 8 weeks.

**Abbreviations:** AUC, area under the curve; CDDP, cisplatin; GEM, gemcitabine; HR, hazard ratio; M, months; ND, not described; Obs, observation alone; OS, overall survival; PEP, primary endpoint; PD, progressive disease; PEM, pemetrexed; PFS, progression-free-survival; Plt, platinum; PTX, paclitaxel; RR, overall response rate; TTP, time to progressive disease; w PTX, weekly paclitaxel.

###### 

Comparison of grade 3--4 adverse events during monotherapy maintenance phase (incidence rate ≥1% in any study)

  Reference                                 Brodowicz et al[@b13-lctt-6-013] (CECOG trial)   Belani et al[@b12-lctt-6-013]   Perol et al[@b14-lctt-6-013] (IFCT-GFPC0502 trial)   Paz-Ares et al[@b16-lctt-6-013] (PARAMOUNT trial)   Ciuleanu et al[@b29-lctt-6-013] (JMEN trial)                    
  ----------------------------------------- ------------------------------------------------ ------------------------------- ---------------------------------------------------- --------------------------------------------------- ---------------------------------------------- ----- ----- ---- -----
  Hematologic                                                                                                                                                                                                                                                                                         
   Leukopenia (%)                           2.3                                              ND                              ND                                                   ND                                                  ND                                             2.2   0     2    \<1
   Neutropenia (%)                          14.9                                             13.3                            1.6                                                  20.8                                                0.6                                            5.8   0     3    0
   Anemia (%)                               2.6                                              9.4                             2.4                                                  2.6                                                 0.6                                            6.4   0.6   3    \<1
   Thrombocytopenia (%)                     1.7                                              9.4                             1.4                                                  6.5                                                 0                                              1.9   0     ND   ND
  Non-hematologic                                                                                                                                                                                                                                                                                     
   Fatigue (%)                              ND                                               3.9                             1.6                                                  ND                                                  ND                                             4.7   1.1   5    \<1
   Alopecia (%)                             4.3                                              ND                              ND                                                   ND                                                  ND                                             ND    ND    ND   ND
   Deterioration of general condition (%)   ND                                               ND                              ND                                                   3.2                                                 3.9                                            ND    ND    ND   ND
   Pneumonia (%)                            ND                                               ND                              ND                                                   3.2                                                 1.3                                            ND    ND    ND   ND
   Anorexia (%)                             ND                                               ND                              ND                                                   0.6                                                 0.6                                            0.3   0     2    0
   Asthenia (%)                             ND                                               ND                              ND                                                   1.9                                                 0                                              ND    ND    ND   ND
   Febrile neutropenia (%)                  ND                                               ND                              ND                                                   ND                                                  ND                                             1.9   0     ND   ND
   Infection (%)                            ND                                               ND                              ND                                                   1.3                                                 0                                              ND    ND    2    0
   Pain (%)                                 ND                                               ND                              ND                                                   ND                                                  ND                                             1.1   0     ND   ND

**Notes:** Study by Brodowicz et al (CECOG trials)[@b13-lctt-6-013] did not describe adverse events in the control arm. No study compared adverse events statistically.

**Abbreviations:** BSC, best supportive care; GEM, gemcitabine; ND, not described; PEM, pemetrexed.

###### 

Phase III studies comparing bevacizumab with pemetrexed or pemetrexed plus bevacizumab

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                          PEP                                              n                                                              Induction                    Maintenance   PFS\                                                                  HR\         OS\   HR\
                                                                                                                                                                                                                                (M)                                                                   *P*-value   (M)   *P*-value
  ------------------------------------------------------------------ ------------------------------------------------ -------------------------------------------------------------- ---------------------------- ------------- --------------------------------------------------------------------- ----------- ----- -----------
  Zinner et al[@b18-lctt-6-013] (PRONOUNCE trial)                    G4PFS                                            361                                                            CBDCA + PEM                  PEM           Survival from random assignment before induction chemotherapy G4PFS                     

                                                                     CBDCA + PTX + Bev ×6 cycles                      Bev                                                                                                                                                                                               

  182                                                                                                                 PEM                                                            3.9                          HR 0.85       10.5                                                                  HR 1.07           

  179                                                                                                                 Bev                                                            2.9                          *P*=0.176     11.7                                                                  *P*=0.615         

                                                                                                                                                                                     PFS                                                                                                                                

  182                                                                                                                 PEM                                                            4.4                          HR 1.06                                                                                               

  179                                                                                                                 Bev                                                            5.5                          *P*=0.61                                                                                              

  Galetta et al[@b17-lctt-6-013] (ERACLE trial)                      QoL[a](#tfn12-lctt-6-013){ref-type="table-fn"}   118                                                                                                                                                                                               

  60                                                                 CDDP + PEM                                       PEM                                                            ND                           HR 0.62       ND                                                                    HR 0.69           

  58                                                                 CBDCA + PTX + Bev ×6 cycles                      Bev                                                            ND                           *P*=0.03      ND                                                                    *P*=0.08          

  Barlesi et al[@b34-lctt-6-013],[@b35-lctt-6-013] (AVAPERL trial)   PFS                                              376 induction                                                  CDDP + PEM + Bev ×4 cycles                                                                                                         

  253 non-PD                                                                                                          Survival from random assignment after induction chemotherapy                                                                                                                                      

  128                                                                                                                 PEM + Bev                                                      7.4                          HR 0.57       17.1                                                                  HR 0.87           

  125                                                                                                                 Bev                                                            3.7                          *P*\<0.0001   13.2                                                                  *P*=0.29          

  Patel et al[@b36-lctt-6-013] (PointBreak trial)                    OS                                                                                                                                                                                                                                                 

  934 randomized                                                                                                      Survival from random assignment before induction treatment                                                                                                                                        

  472                                                                CBDCA + PEM + Bev                                PEM + Bev                                                      6.0                          HR 0.83       12.6                                                                  HR 1.00           

  467                                                                CBDCA + PTX + Bev ×4 cycles                      Bev                                                            5.6                          *P*=0.012     13.4                                                                  *P*=0.949         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

EQ5D Index (EQ5D-I) and EQ5D-VAS (Euro-QoL questionnaire) at 12 weeks during maintenance therapy.

**Abbreviations:** Bev, bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; G4PFS, progression-free survival without grade 4 adverse event; HR, hazard ratio; M, months; ND, not described; OS, overall survival; PD, progressive disease; PEM, pemetrexed; PEP, primary endpoint; PFS, progression-free survival; PTX, paclitaxel; QoL, quality of life.

###### 

Comparison in cost-effectiveness of direct medical cost between maintenance with pemetrexed *vs*. observation alone after induction chemotherapy: study designs and results

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                         Methods, costs and outcomes discount, study perspective, time frame and reference year for cost   Data sources                                                                                               Study population                                                                                                             Regime            Cost        LYG or OS   QALY   ICER[a](#tfn14-lctt-6-013){ref-type="table-fn"}/LYG   ICER[a](#tfn14-lctt-6-013){ref-type="table-fn"}/QALY
  ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ----------------- ----------- ----------- ------ ----------------------------------------------------- ------------------------------------------------------
  Greenhalgh et al[@b19-lctt-6-013] (UK)                            ERG report reviewing the manufacturer's evidence submission, de novo economic model\              Clinical parameters: RCT (JMEN trial)                                                                      Subgroup of 481 patients in JMEN trial                                                                                       PEM maintenance               15.5 M                                                                   
                                                                    Cost discount ND\                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                    Time frame; lifetime\                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                    Reference year; ND                                                                                                                                                                                                                                                                                                                                                                                                                               

   Submitted base case[b](#tfn15-lctt-6-013){ref-type="table-fn"}   £17,455                                                                                                                                                                                                      0.9697                                                                                                                       ND                £33,732                                                                              

   Combined effect of changes                                       £20,925                                                                                                                                                                                                      0.9539                                                                                                                       ND                £47,239                                                                              

  BSC alone                                                                                                                                                           10.3 M                                                                                                                                                                                                                                                                                                                                         

   Submitted base case[b](#tfn15-lctt-6-013){ref-type="table-fn"}   £8,318                                                                                                                                                                                                       0.6988                                                                                                                                                                                                                              

   Combined effect of changes                                       £8,370                                                                                                                                                                                                       0.6881                                                                                                                                                                                                                              

  Klein et al[@b20-lctt-6-013] (US)                                 Semi-Markov model\                                                                                Clinical parameters: RCT (JMEN, ATLAS, SATURN trials)\                                                     Advanced NSCLC patients who have completed first-line platinum double chemotherapy without progression                       PEM maintenance                                                                                        
                                                                    Discounted at 3%\                                                                                 Cost: Medicare reimbursement rate and analysis of claim database (PharMetrics)                                                                                                                                                                                                                                                                 
                                                                    US payer's perspective\                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                    Time frame; 3 years\                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                    Reference; 2009 US\$                                                                                                                                                                                                                                                                                                                                                                                                                             

   Non-SQ                                                           \$96,774                                                                                          1.3412 Y                                                                                                                                                                                                                                \$122,371                                                                                              

   All NSCLC                                                        \$89,289                                                                                          1.2434 Y                                                                                                                                                                                                                                \$205,597                                                                                              

  BSC alone                                                                                                                                                                                                                                                                      ND                                                                                                                                             ND                                                                                   

   Non-SQ                                                           \$64,830                                                                                          1.0802 Y                                                                                                                                                                                                                                                                                                                                       

   All NSCLC                                                        \$61,036                                                                                          1.1060 Y                                                                                                                                                                                                                                                                                                                                       

  Tsuchiya et al[@b22-lctt-6-013] (Japan)                           Markov model\                                                                                     Clinical parameters: RCT (JMEN trial)                                                                      Advanced NSCLC (either non-SQ or all histology), Japanese men in their 60s, height 164.6 cm, weight 64.5 kg, BSA 1.70 m^2^   PEM maintenance                                                                                        
                                                                    Discounted at 3% annually\                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                    Japanese healthcare payer perspective\                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                    Time frame; ND\                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                    Reference; 2009 US\$ (assumed US \$1 to JPY 115)                                                                                                                                                                                                                                                                                                                                                                                                 

   Non-SQ                                                           \$68,536                                                                                          489.4 D                                                                                                    0.7321                                                                                                                       \$80,563          \$150,115                                                                            

   All NSCLC                                                        \$64,409                                                                                          451.8 D                                                                                                    0.6770                                                                                                                       \$109,024         \$203,022                                                                            

  BSC alone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

   Non-SQ                                                           \$39,872                                                                                          359.5 D                                                                                                    0.5411                                                                                                                                                                                                                              

   All NSCLC                                                        \$38,843                                                                                          366.2 D                                                                                                    0.5511                                                                                                                                                                                                                              

  Matter-Walstra et al[@b21-lctt-6-013] (Switzerland)               Markov model\                                                                                     Clinical parameters: RCT (JMEN trial) Cost: literature                                                     Advanced non-SQ\                                                                                                             PEM maintenance   €99,705     15.6 M      0.82   ND                                                    €106,202
                                                                    No discount\                                                                                                                                                                                                 NSCLC, BSA 1.77 m^2^                                                                                                                                                                                                                
                                                                    Swiss health care system perspective\                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                    Time frame; lifetime\                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                    Reference; 2010 Swiss prices (€0.72 / Swiss franc)                                                                                                                                                                                                                                                                                                                                                                                               

  BSC alone                                                         €71,316                                                                                           10.7 M                                                                                                     0.56                                                                                                                                                                                                                                

  Zeng et al[@b23-lctt-6-013] (People' Republic of China)           Markov model\                                                                                     Clinical parameters: RCT (PARAMOUNT trial)\                                                                Advanced non-SQ\                                                                                                             PEM maintenance                                                                                        
                                                                    Discounted at 3% annually\                                                                        Cost: BSC and AE costs from literature, market share and local charges in the People's Republic of China   NSCLC, weight 65 kg, BSA 1.72 m^2^                                                                                                                                                                                                  
                                                                    Chinese health care system perspective\                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                    Time frame; 1,2,5 and 10 year\                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                    Reference; 2010 US\$ (assumed 1 US\$ to 6.6515 Chinese yuan)                                                                                                                                                                                                                                                                                                                                                                                     

   1-year                                                           \$36,443                                                                                          0.760 Y                                                                                                    0.440                                                                                                                        \$193,796         \$183,589                                                                            

   2-year                                                           \$55,532                                                                                          1.140 Y                                                                                                    0.631                                                                                                                        \$99,183          \$126,353                                                                            

   5-year                                                           \$72,103                                                                                          1.444 Y                                                                                                    0.776                                                                                                                        \$80,792          \$124,766                                                                            

   10-year                                                          \$73,955                                                                                          1.477 Y                                                                                                    0.791                                                                                                                        \$79,134          \$124,793                                                                            

  BSC alone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

   1-year                                                           \$28,255                                                                                          0.718 Y                                                                                                    0.396                                                                                                                                                                                                                               

   2-year                                                           \$44,181                                                                                          1.026 Y                                                                                                    0.541                                                                                                                                                                                                                               

   5-year                                                           \$54,790                                                                                          1.230 Y                                                                                                    0.637                                                                                                                                                                                                                               

   10-year                                                          \$55,607                                                                                          1.245 Y                                                                                                    0.644                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Incremental pemetrexed maintenance to BSC;

data based upon the evidence submission from the manufacturer (Eli Lilly) to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process.

**Abbreviations:** AE, adverse events; BSA, body surface area; BSC, best supportive care; D, days; ERG, evidence review group; ICER, incremental cost-effectiveness ratio; JPY, Japanese Yen; LYG, life-year gained; M, months; ND, not described; NSCLC, non-small cell lung cancer; OS, overall survival; PEM, pemetrexed; QALY, quality-adjusted life-year; RCT, randomized controlled trial; SQ, squamous cell carcinoma; Y, years.

###### 

Comparison in cost-effectiveness of direct medical cost between pemetrexed and other maintenance therapy: study designs and results

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                            Methods, costs and outcomes discount, study perspective, time frame and reference year for cost   Data sources                                                                    Study population                    Regime                         Costs     LYG / OS   QALY   ICER / LYG   ICER / QALY
  ------------------------------------ ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ----------------------------------- ------------------------------ --------- ---------- ------ ------------ -------------
  Klein et al[@b20-lctt-6-013]\        See Klein et al[@b20-lctt-6-013]                                                                                                                                                                                      PEM                                                                     
  (US)                                                                                                                                                                                                                                                                                                                               

   Non-SQ                              \$96,774                                                                                          1.3412 Y                                                                        ND                                                                                                          

   All NSCLC                           \$89,289                                                                                          1.2434 Y                                                                        ND                                                                                                          

  Erlotinib                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                             Incremental PEM to Erlotinib                                            

   Non-SQ                              \$72,300                                                                                          1.1784 Y                                                                        ND                                  \$ 150,260                     ND                                       

   All NSCLC                           \$71,147                                                                                          1.1854 Y                                                                        ND                                  \$ 312,341                     ND                                       

  Bev (15 mg/kg)                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                             Incremental Bev to PEM                                                  

   Non-SQ                              \$105,961                                                                                         1.2933 Y                                                                        ND                                  Dominated                      ND                                       

  Dickson et al[@b27-lctt-6-013]\      ERG report reviewing the manufacturer's evidence submission, de novo economic model\              Clinical parameters: RCT (SATURN, JMEN trial)                                   Model 1; SD, All\                   PEM                                                                     
  (UK)                                 Cost discount; ND\                                                                                                                                                                NSCLC: Erl vs. placebo\                                                                                     
                                       Time frame; lifetime\                                                                                                                                                             Model 2; SD, SQ: Erl vs. placebo\                                                                           
                                       Reference year; ND                                                                                                                                                                Model 3; SD, non-SQ: Erl vs. PEM                                                                            

   SD, non-SQ                          £26,608                                                                                           1.5495 Y                                                                        0.9229                              ND                             ND                                       

  Erlotinib                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                             Incremental PEM to Erlotinib                                            

  SD, non-SQ                           £18,148                                                                                           1.4213 Y                                                                        0.8222                              ND                             £84,029                                  

  Nuijten et al[@b28-lctt-6-013]\      Cross-market cost comparison\                                                                     Clinical parameters: RCT (SATURN, JMEN trial)\                                  Advanced NSCLC                      PEM                                      ND         ND     ND           ND
  (France, Germany, Italy and Spain)   Perspective of national health-care decision-makers or purchasers.\                               Cost; literatures, National drug tariffs for France, Germany, Italy and Spain                                                                                                               
                                       Time frame; monthly\                                                                                                                                                                                                                                                                          
                                       Reference; 2008 Euro                                                                                                                                                                                                                                                                          

   France                              €3,453                                                                                                                                                                                                                                                                                        

   Germany                             €5,534                                                                                                                                                                                                                                                                                        

   Italy                               €2,921                                                                                                                                                                                                                                                                                        

   Spain                               €3,164                                                                                                                                                                                                                                                                                        

  Erlotinib                                                                                                                              ND                                                                              ND                                  ND                             ND                                       

   France                              €2,140                                                                                                                                                                                                                                                                                        

   Germany                             €2,732                                                                                                                                                                                                                                                                                        

   Italy                               €1,518                                                                                                                                                                                                                                                                                        

   Spain                               €2,048                                                                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** Bev, bevacizumab; Erl, erlotinib; ERG, Evidence Review Group; ICER, incremental cost-effectiveness ratio; LYG, life-year gained; ND, not described; NSCLC, non-small-ell lung cancer; OS, overall survival; PEM, pemetrexed; QALY, quality-adjusted life-year; RCT; randomized controlled trial; SD, stable disease; SQ, squamous cell carcinoma; Y, years.

###### 

Comparison of efficacy of the first-line combination of pemetrexed plus platinum followed by pemetrexed maintenance between Japanese Phase II studies and multinational Phase III studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                            Country   Phase   Patients                      Treatment                     PFS and OS from induction (M)
  ---------------------------------------------------- --------- ------- ----------------------------- ----------------------------- -------------------------------
  Ciuleanu et al[@b29-lctt-6-013]\                     Multi     R-p3    441 NSCLC, including 26% SQ   Plt-based doublet ×4 cycles   PFS 7.7
  (JMEN trial)                                                                                                                       

  → PEM maintenance                                    OS 16.5                                                                       

  Paz-Ares et al[@b15-lctt-6-013],[@b16-lctt-6-013]\   Multi     R-p3    359 non-SQ                    CDDP + PEM ×4 cycles          PFS ND
  (PARAMOUNT trial)                                                                                                                  

  → PEM maintenance                                    OS 16.9                                                                       

  Okamoto et al[@b33-lctt-6-013]\                      Japan     S-p2    109 non-SQ                    CBDCA + PEM ×4 cycles         PFS 5.7
  (JACAL trial)                                                                                                                      

  → PEM maintenance                                    OS 20.2                                                                       

  Minami et al[@b32-lctt-6-013]\                       Japan     S-p2    34 non-SQ                     CBDCA + PEM ×4 cycles         PFS 5.2
  (OULCSG0902 trial)                                                                                                                 

  → PEM maintenance                                    OS 23.3                                                                       

  Karayama et al[@b31-lctt-6-013]                      Japan     R-p2    26 non-SQ                     CBDCA + PEM ×4 cycles         PFS 7.4

  → PEM maintenance                                    OS 25.0                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CBDCA, carboplatin; CDDP, cisplatin; M, month; Multi, multinational; ND, not described; NSCLC, non-small-cell lung cancer; OS, overall survival; PEM, pemetrexed; PFS, progression-free survival; Plt, platinum; R-p2, randomized phase II; R-p3, randomized phase III; S-p2, single-arm phase II; SQ, squamous cell carcinoma.

###### 

Comparison of grade 3--4 adverse events during maintenance phase (incidence rate ≥1% in any study)

  Reference                         Barlesi et al[@b34-lctt-6-013],[@b35-lctt-6-013] (AVAPERL trial)   Patel et al[@b36-lctt-6-013] (PointBreak trial)                                                     
  --------------------------------- ------------------------------------------------------------------ ------------------------------------------------- ------------------------------------------------- ------
  Hematologic                                                                                                                                                                                              
   Leukopenia (%)                   ND                                                                 ND                                                ND                                                ND
   Neutropenia (%)                  5.6                                                                0                                                 14.0                                              11.4
   Anemia (%)                       3.2                                                                0                                                 11.0[a](#tfn20-lctt-6-013){ref-type="table-fn"}   0.3
   Thrombocytopenia (%)             0                                                                  0                                                 7.2[a](#tfn20-lctt-6-013){ref-type="table-fn"}    2.3
  Non-hematologic                                                                                                                                                                                          
   Fatigue (%)                      2.4                                                                1.7                                               9.6[a](#tfn20-lctt-6-013){ref-type="table-fn"}    1.7
   Hypertension (%)                 4.8                                                                2.5                                               3.1                                               6.0
   Sensory neuropathy (%)           ND                                                                 ND                                                0[a](#tfn20-lctt-6-013){ref-type="table-fn"}      4.7
   Thromboembolic events (%)        ND                                                                 ND                                                2.4                                               0.7
   Pulmonary embolism (%)           0.8                                                                1.7                                               ND                                                ND
   GI or pulmonary hemorrhage (%)   ND                                                                 ND                                                1.4                                               0
   Febrile neutropenia (%)          0.8                                                                0                                                 1.0                                               0

**Notes:** AVAPERL study did not describe the result of statistical comparison.

Statistically significant (*P*\<0.05).

**Abbreviations:** Bev, bevacizumab; GI, gastrointestinal; ND, not described; PEM, pemetrexed.
